Verona Pharma pleased with RPL554 trial top-line results 1 234 567

Verona Pharma pleased with RPL554 trial top-line results

livecharts.co.uk

Clinical-stage biopharmaceutical company Verona Pharma announced top-line results from its clinical pharmacokinetic (PK) trial in the United States on Wednesday, which it said demonstrated that inhaled RPL554 is an "appropriate form of administration" for patients with chronic obstructive pulmonary disease (COPD) and other respiratory disorders.

Full news

Share:

More:

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567